Enzo Health
AI-powered documentation co-pilot for home health facilities
Website: https://www.enzo.health/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Enzo Health |
| Tagline | AI-powered documentation co-pilot for home health facilities |
| Headquarters | Lehi, Utah, United States |
| Founded | 2023 |
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry | Healthtech (post-acute / home health) |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Pre-Seed |
| Total Disclosed | ~$1.5M [Crunchbase, May 2024] |
Links
PUBLIC
- Website: https://www.enzo.health/
- LinkedIn: https://www.linkedin.com/company/enzo-health
- Careers: https://jobs.ashbyhq.com/enzo-health
Executive Summary
PUBLIC
Enzo Health is an early-stage Utah healthtech company building an AI documentation co-pilot purpose-built for home health agencies, a workflow segment where clinicians routinely spend more time charting than at the bedside. The company was founded in 2023 and is headquartered in Lehi, Utah, with a pre-seed round of approximately $1.5 million closed in May 2024 [Crunchbase, May 2024]. Its product is positioned as an all-in-one stack covering documentation, intake, and coding for home care services, with HIPAA compliance described as a core design constraint rather than an afterthought [Enzo Health, 2024]. The capital base, while small, comes from two investors with credible early-stage records in software and Utah-based technology: Soma Capital and Tandem Ventures [Crunchbase, 2024] [Tandem Venture Partners, 2024]. In July 2025 the company announced an advisory board of named home-based-care operators and clinicians, a step typically taken to compress the enterprise sales cycle in a regulated buyer environment [Business Wire, 2025]. Over the next 12 to 18 months, the questions worth tracking are whether Enzo can convert pilot agencies into paid, multi-site contracts, whether it can carve a defensible niche around home health specifically rather than the broader post-acute category, and whether it raises a priced seed round on the strength of that traction. The company is small, quiet, and early, but it sits in a workflow that operators have repeatedly told industry press is broken.
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, Tandem Ventures, and Business Wire.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech, home health and post-acute care |
| Technology Type | AI / Machine Learning, clinical NLP |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | ~$1.5M pre-seed (Soma Capital, Tandem Ventures) |
Company Overview
PUBLIC
Enzo Health was founded in 2023 and incorporated as Enzo Health Technology, Inc., with operations based in Lehi, Utah [Crunchbase, 2024] [PitchBook, 2024]. The company describes itself as a documentation co-pilot for post-acute healthcare, with a current product focus on home health agencies, the segment of the care continuum that delivers skilled nursing and therapy services in patients' homes under Medicare and Medicaid reimbursement rules [Crunchbase, 2024] [Enzo Health, 2024]. The founder of record in public databases is Zach Newman; the wider founding team is not fully disclosed in public filings, though the company has stated it was built by "seasoned clinicians and technologists" [Yahoo Finance, 2024].
The earliest publicly traceable institutional milestone is participation in Soma Capital's Soma Fellows program, with the company appearing in the S24 demo day cohort [Soma Fellows, 2024]. That program led into the $1.5 million pre-seed round closed on May 1, 2024, with Soma Capital and Tandem Ventures named as backers [Crunchbase, May 2024] [Crunchbase, 2024]. In July 2025 the company announced an advisory board described as "industry titans" in home-based care, a deliberate signal aimed at agency operators who typically buy from vendors with clinical credibility [Business Wire, 2025] [Yahoo Finance, 2024]. Headcount sits in the 1 to 10 band per Crunchbase, consistent with a pre-seed team [Crunchbase, 2024].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and Business Wire.
Product and Technology
MIXED
Enzo Health's marketed product is a HIPAA-compliant, home-health-specific software suite covering documentation, intake, and coding, with AI features positioned as the core differentiator rather than an add-on layer [Enzo Health, 2024]. In Crunchbase's company description and in Tandem Ventures' portfolio page, the product is framed more narrowly as an "AI-powered documentation co-pilot" that gives agency owners compliance automation while increasing revenue, language that suggests the initial wedge is the OASIS and visit-note workflow that drives both reimbursement and survey risk in home health [Crunchbase, 2024] [Tandem Venture Partners, 2024].
In practical terms, the company is competing for the clinician's time at the point of charting. The product claim of an "all-in-one" intake, documentation, and coding stack implies the company is targeting agencies that today stitch together a legacy EHR, a separate coding vendor, and manual QA review, a configuration common at small and mid-sized home health operators [Enzo Health, 2024]. The presence of an open PRN Quality Assurance Nurse role on the company careers site is consistent with a human-in-the-loop QA model for AI-generated documentation, a design pattern that several clinical AI startups have adopted to satisfy compliance review while training their underlying models [AshbyHQ, 2026].
Public technical detail beyond the marketing surface is thin. Enzo has not published model architecture, dataset provenance, or named EHR integration partners, and there is no Crunchbase tech-stack disclosure of consequence beyond a generic growth and CB Rank score [Crunchbase, 2024]. For diligence purposes, the meaningful unknowns are whether the AI layer is built on a fine-tuned open model or a frontier API, how the company handles PHI segregation in inference, and which home health EHRs (HCHB, WellSky, MatrixCare, Axxess) it integrates with at the data layer.
Data Accuracy: YELLOW -- Product claims confirmed by company website and Tandem Ventures; technical implementation not publicly documented.
Market Research and Opportunity
PUBLIC
The home health software market is being reshaped by two forces arriving at the same time: a demographic surge in Medicare-eligible patients choosing home-based care, and a regulatory regime (PDGM, OASIS-E, value-based purchasing) that has made documentation accuracy directly determinative of agency revenue.
Market sizing specific to AI documentation in home health is not yet a standard category in major analyst reports, so the relevant frame is the broader home health software stack and the analogous ambient clinical documentation market that scaled rapidly in acute care over the past two years. Enzo's own positioning emphasizes compliance automation tied to revenue lift, which mirrors the value proposition that home health operators describe in trade press: documentation errors translate directly into denied claims, lower case-mix weights, and survey citations [Tandem Venture Partners, 2024]. The company has not published a TAM figure, and no third-party research firm in the captured sources sizes the segment with a number this analyst is willing to cite without further primary research.
The demand drivers are nevertheless concrete. The Centers for Medicare and Medicaid Services has continued to expand value-based purchasing in home health, which raises the stakes on outcome and visit documentation. Workforce shortages among home health nurses are well documented in industry press, and any tool that materially reduces charting time has a direct retention-and-capacity argument attached to it. Adjacent and substitute markets include legacy home health EHRs (HCHB, WellSky, MatrixCare, Axxess), specialist coding vendors, outsourced QA firms based largely in the Philippines and India, and the new wave of ambient AI scribes built primarily for clinic and hospital settings. Each of these substitutes solves part of the problem; none, on the public evidence, solves the home-health-specific stack end to end.
| Sizing claim | Value | Source |
|---|---|---|
| Enzo disclosed pre-seed funding | $1.5M (May 2024) | [Crunchbase, May 2024] |
| Tandem Ventures Fund I size | $50M (Sept 2025) | [Utah Business, 2025] |
the cited numbers are about Enzo's funding context rather than its end-market, which underscores that the home-health AI documentation category is still pre-consensus among research firms. That is a feature, not a bug, for an early entrant willing to define the category.
Data Accuracy: YELLOW -- Funding figures confirmed by Crunchbase and Utah Business; market sizing not available from cited sources.
Competitive Landscape
MIXED
Enzo is positioning into a market where the incumbents own the system of record but have been slow to ship native generative AI, and where new entrants are mostly attacking the acute-care scribe market rather than the home health workflow.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Enzo Health | AI documentation, intake, coding co-pilot for home health | Pre-Seed, ~$1.5M (May 2024) | Home-health-specific workflow and compliance focus | [Crunchbase, May 2024] [Enzo Health, 2024] |
| Netsmart | Enterprise EHR and post-acute platform incumbent | Private, PE-backed (mature) | Installed base across post-acute and behavioral health | [Crunchbase, 2024] |
The segment-by-segment map breaks down roughly as follows. The incumbent EHRs in home health (Netsmart, plus the broader cohort of HCHB, WellSky, MatrixCare, Axxess that operators commonly evaluate alongside it) own the system of record and have multi-year contracts with the agencies that account for the bulk of national visit volume. Their advantage is distribution and switching cost; their exposure is that generative AI is not yet a first-class part of their charting experience for most customers. A second cohort of ambient scribe startups has raised significant capital around the acute and ambulatory clinic use case, but home health visits, which are conducted in a patient's living room, often without reliable connectivity, and against a OASIS assessment rather than a SOAP note, are a meaningfully different product surface. A third cohort of outsourced coding and QA firms competes on labor arbitrage rather than software, and would be most directly displaced if Enzo's coding module performs at parity.
Enzo's defensible edge today, on the public evidence, is focus. By committing to home health rather than the entire post-acute continuum, the company can shape its data model around OASIS-E, PDGM grouping logic, and visit-note conventions that general-purpose scribes treat as edge cases. That focus is reinforced by the July 2025 advisory board composed of home-based care operators, which functions as both distribution and product-validation infrastructure [Business Wire, 2025]. The perishability of that edge is the obvious question: focus is replicable by any well-funded scribe vendor that decides home health is worth a vertical SKU.
Where Enzo is most exposed is on the integration and trust axis against Netsmart and the other incumbent EHRs. An incumbent that ships even a competent in-product AI assistant to its installed base captures the workflow without any procurement event for the customer, which is the highest-friction step in selling to home health agencies. A plausible 18-month scenario: Enzo wins if a regional home health chain in the 50-to-200 location range standardizes on it and publishes a measurable case-mix or QA outcome; Enzo loses ground if Netsmart or one of the other top-three home health EHRs ships a native AI documentation feature bundled at no incremental cost to existing customers before Enzo has signed reference accounts.
Data Accuracy: YELLOW -- Subject and Netsmart confirmed by Crunchbase; broader competitive map drawn from category knowledge and not from a single cited report.
Opportunity
PUBLIC
If Enzo executes against its stated wedge, the prize is becoming the default AI documentation layer for the home health segment of US post-acute care, a segment that currently runs on a small number of legacy EHRs and a large amount of nurse overtime.
The headline opportunity. The single largest outcome reachable from Enzo's current position is to become the category-defining AI co-pilot for home health agencies, the way certain ambient scribes have become the default in ambulatory clinics. The cited evidence makes this aspirational rather than fanciful in three ways. First, the company has chosen a vertical (home health) rather than a horizontal (all clinical documentation), which historically is how vertical SaaS winners get built. Second, its pre-seed investors, Soma Capital and Tandem Ventures, have explicit early-stage software theses, with Tandem having recently closed a $50 million Fund I to back early-stage technology companies, including Enzo [Utah Business, 2025] [Tandem Venture Partners, 2025]. Third, the July 2025 advisory board is composed of named home-based-care operators, which is the most efficient distribution shortcut available to a pre-seed vendor selling to a fragmented buyer base [Business Wire, 2025].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Vertical category leader | Enzo becomes the standalone AI layer most home health agencies bolt onto their existing EHR | A reference deployment at a multi-state agency that publishes measurable QA and revenue results | Advisory board gives direct access to such operators [Business Wire, 2025] |
| Acquired by an incumbent EHR | Netsmart or a peer acquires Enzo to ship native AI rather than build it | Incumbent renewal cycle pressure as agencies ask AI questions in RFPs | Pre-seed pricing is digestible for a PE-backed incumbent [Crunchbase, 2024] |
| Platform expansion into adjacent post-acute | Enzo extends from home health into hospice and home-based primary care on the same data model | Successful first vertical plus a Series A round | Crunchbase already describes the company as "post-acute" rather than home-health-only [Crunchbase, 2024] |
What compounding looks like. The flywheel in clinical AI documentation is well understood: every charted visit produces labelled training data that improves model accuracy, which improves coding and reimbursement outcomes, which improves customer ROI and willingness to expand seats and refer peers. In home health specifically, where agencies talk to each other through state associations and where a meaningful share of operators are independent or small-chain, peer reference is unusually load-bearing. The advisory board move suggests Enzo understands this; whether the data flywheel is actually producing measurable accuracy gains is not yet publicly evidenced [Business Wire, 2025].
The size of the win. A credible comparable for the upper end of the outcome range is the valuation trajectory of vertical clinical software companies that became the system of intelligence layered on top of legacy EHRs. Public market comparables and recent private rounds in clinical AI suggest that a company that becomes the default documentation layer for a defined US clinical segment can plausibly support a nine-to-ten-figure outcome (scenario, not a forecast). The lower end of the range is an acquisition by an incumbent EHR for the team and product at a multiple of invested capital that returns the pre-seed fund but does not generate venture-scale outcomes for later investors. Both ends of that range are reachable from the current position; which end Enzo lands on will be decided by the next 18 months of customer evidence.
Data Accuracy: YELLOW -- Scenario inputs grounded in Crunchbase, Business Wire, and Tandem Ventures sources; outcome ranges are scenario framing and not a forecast.
Sources
PUBLIC
[Crunchbase, 2024] Enzo Health - Crunchbase Company Profile and Funding | https://www.crunchbase.com/organization/enzo-health
[Crunchbase, May 2024] Pre Seed Round - Enzo Health - 2024-05-01 | https://www.crunchbase.com/funding_round/enzo-health-pre-seed--c169c5e2
[Crunchbase, 2024] Enzo Health - Tech Details | https://www.crunchbase.com/organization/enzo-health/tech_details
[Crunchbase, 2024] Enzo Health - Funding, Financials, Valuation and Investors | https://www.crunchbase.com/organization/enzo-health/company_financials
[Tandem Venture Partners, 2024] Enzo Health - The Next Gen Of Founders | https://tandeminvest.com/companies/enzo-health/
[Tandem Venture Partners, 2025] Tandem Ventures Announces $50M Fund I | https://tandeminvest.com/front-page/news/tandem-ventures-announces-50m-fund-i/
[PitchBook, 2024] Enzo Health 2026 Company Profile: Valuation, Funding and Investors | https://pitchbook.com/profiles/company/607289-41
[Enzo Health, 2024] Home Health AI and Documentation Software | https://www.enzo.health/
[Yahoo Finance, 2024] Enzo Health Forms Advisory Board of Industry Titans to Drive Innovation in Home-Based Care | https://finance.yahoo.com/news/enzo-health-forms-advisory-board-164700665.html
[Business Wire, 2025] Enzo Health Forms Advisory Board of Industry Titans to Drive Innovation in Home-Based Care | https://www.businesswire.com/news/home/20250708995526/en/Enzo-Health-Forms-Advisory-Board-of-Industry-Titans-to-Drive-Innovation-in-Home-Based-Care
[AshbyHQ, 2026] PRN Quality Assurance Nurse at Enzo Health | https://jobs.ashbyhq.com/enzo-health/32d37710-2da9-4aba-a374-7962e4b4c01c
[Soma Fellows, 2024] Soma Fellows S24 Demo Day | https://www.somafellows-demoday.com/
[Utah Business, 2025] Tandem Ventures announces $50M Fund I | https://www.utahbusiness.com/press-releases/2025/09/18/tandem-ventures-announces-50-million-fund-capital-firm-utah/
[Tandem Ventures, 2024] Enzo Health | Tandem Ventures Job Board | https://jobs.tandeminvest.com/companies/enzo-health-2
[LinkedIn, 2024] Enzo Health company page | https://www.linkedin.com/company/enzo-health
Articles about Enzo Health
- Enzo Health Wants to Take the Paperwork Off the Home Health Nurse's Clipboard — The Lehi, Utah pre-seed startup is building a HIPAA-compliant documentation co-pilot for post-acute agencies serving homebound patients.